GlassScriptPhysician profile
Wendy Chung
NPI 1972578540
$37,436.72
in general payments reported to CMS, 2019-2025
13 companies · $3,549 in 2025
The $3,549 reported for 2025 was more than what 75% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $2,041 · 2021: $3,916 · 2022: $5,736 · 2023: $9,104 · 2025: $3,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,070 · Travel and Lodging: $3,667 · Consulting Fee: $510 · Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,070.00 |
| Travel and Lodging | $3,667.32 |
| Consulting Fee | $510.00 |
| Food and Beverage | $405.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $9,076.66 | 2019-2021 | |
| Biomarin Pharmaceutical INC. | $6,134.84 | 2023 | Voxzogo 1.2mg |
| Acadia Pharmaceuticals INC | $5,400.00 | 2019 | |
| Illumina, INC. | $3,540.68 | 2022-2025 | Genetic Disease Testing |
| Genzyme Corporation | $3,478.76 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $2,925.00 | 2022 | |
| Pfizer INC. | $1,800.00 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $1,575.00 | 2021 | |
| Glaxosmithkline, LLC. | $1,510.78 | 2019 | |
| Sarepta Therapeutics, INC. | $1,485.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $510.00 | 2023 | Vpriv |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.